INVEST IN AFRICA NOW

Set-up your Business in Africa's Key Industrial Zones

Name *

Email *

Phone No. *

Investment Sector

Investment Opportunity

Investment Budget (USD)

How may we assist you?

*Note: Name, Email and Phone Number are mandatory.

I agree to the AFI privacy policy.*

I agree to receive e-communications from AFI.

THANK YOU

Our team will get back to you shortly.

Home / Rwanda / BSEZ / API & Medicines

Rwanda | BSEZ

API & Medicines opportunity

The BSEZ zone in Africa offers a compelling opportunity for businessmen to invest in API and medicines. This region is strategically positioned to capitalize on the growing demand for pharmaceuticals across the continent, driven by rapid population growth, increasing urbanization, and rising healthcare needs.

API & Medicines by-product markets

Veterinary Medicines

Generic Medicines

Nutraceuticals

Personalized Medicine

Bulk Active Pharmaceutical Ingredients

Pharmaceutical Intermediates

API & MEDICINE BUSINESS IN BSEZ, RWANDA: KEY ADVANTAGES FOR INVESTORS

Market Growth: Africa's pharmaceutical market is projected to reach USD 70 billion by 2030, growing at a CAGR of 5.9%, with healthcare spending expected to rise as governments prioritize access and pharmaceutical development.
Import Dependency: Currently, 70-80% of pharmaceuticals in Africa are imported, underscoring the critical need for developing robust local production capabilities to ensure self-sufficiency and reduce reliance on foreign supplies.
Strategic Location and Market Access: The BSEZ offers direct access to Africa's rapidly growing pharmaceutical market and proximity to major ports and logistics hubs for efficient continental distribution.
Favorable Economic Policies and Incentives: Investors in the BSEZ will benefit greatly from tax incentives, reduced tariffs, and streamlined regulations, along with robust government support for pharmaceutical manufacturing and healthcare infrastructure development.
Growing Demand for Pharmaceuticals: Africa's pharmaceutical market is among the fastest-growing globally, driven by a population projected to reach 2.5 billion by 2050, increasing prevalence of chronic diseases, and a rising middle class, boosting demand for high-quality medicines.
Untapped Market Potential: Currently, a significant portion of Africa's pharmaceuticals are imported. Investing in local API and medicine manufacturing can fill this gap, and establishing production facilities in the BSEZ will reduce import dependency and ensure a stable supply of essential medicines.
Cost-Effective Production: Competitive labor costs and access to raw materials lower production expenses compared to other regions, while efficient supply chain management within Rwanda further enhances cost-effectiveness.